Tango Therapeutics
TNGX
21.73
-0.98
-4.32%
Tango Therapeutics
US · TNGX
#2322 by market cap
Listed 1970
21.73
-0.98
-4.32%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:41
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 11 in the most recent period (2026/Q3).
- Total institutional ownership rose 8.6 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 136.60% +8.57pp
- Institutions
- 307 +11
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund58.82%
Hedge Fund50.96%
VC/PE Fund18.75%
Public Company7.21%
Individual/Insider1.06%
Private Company0.30%
Insurance Company0.26%
Government Pension Fund0.23%
Top holders as of 2026-10-30
FMR
14.92% · 25.29M sh
RTW Investments, LP
8.20% · 13.90M sh
BlackRock
7.76% · 13.14M sh
Farallon Capital Management, L.L.C.
7.24% · 12.28M sh
Boxer Capital Management, LLC
6.42% · 10.88M sh
The Goldman Sachs Group, Inc.
5.69% · 9.65M sh
TCG Crossover Management, LLC
5.36% · 9.08M sh
State Street Global Advisors
4.32% · 7.32M sh
Vanguard Capital Management, LLC
4.08% · 6.87M sh
Artal Group S.A.
4.00% · 6.78M sh
Third Rock Ventures, LLC
3.90% · 6.57M sh
T. Rowe Price Group, Inc.
3.90% · 6.60M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 25 buys · 22 sells
| Name | Role | Stake |
|---|---|---|
| Barbara Weber | Officer | 0.92% |
| Daniella Beckman | Former Chief Financial Officer | 0.08% |
| Mace Rothenberg | Independent Director | 0.02% |
| John Ketchum | Independent Director | 0.01% |
| Adam Crystal | President of Research & Development | 0.01% |
| Lesley Calhoun | Independent Director | 0.01% |
| Malte Peters | Chief Executive Officer | 0.01% |
| Alexis Borisy | Former Lead Independent Director | 0.01% |
| Jessica Newcomb | -- | 0.00% |
| Third Rock Ventures, LLC | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-01 | Jessica Newcomb | -- | Automatic Disposition | -7,031 | $22.28–22.98 |
| 2026-11-01 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -5,000 | $2.91–22.99 |
| 2026-09-30 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -27,000 | $5.20–25.32 |
| 2026-09-21 | Jessica Newcomb | -- | Automatic Disposition | -8,200 | $22.80–25.17 |
| 2026-08-31 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -27,000 | $5.20–22.37 |
| 2026-08-02 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -27,000 | $5.20–27.35 |
| 2026-06-30 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -27,000 | $5.20–30.25 |
| 2026-06-18 | Robert Azelby | Independent Chairperson | Other Acquisition | +5,740 | -- |
| 2026-06-18 | Robert Azelby | Independent Chairperson | Other Derivative Acquisition | +35,910 | $27.97 |
| 2026-06-16 | Nextech Invest Ltd. | -- | Intent to Sell (Form 144) | -3,766,081 | $30.10 |
| 2026-06-10 | Daniella Beckman | Former Chief Financial Officer | Intent to Sell (Form 144) | -1,791,726 | $28.76 |
| 2026-06-09 | Daniella Beckman | Former Chief Financial Officer | Intent to Sell (Form 144) | -4,446 | $30.00 |
| 2026-06-04 | Mace Rothenberg | Independent Director | Other Acquisition | +4,000 | -- |
| 2026-06-04 | Mace Rothenberg | Independent Director | Other Derivative Acquisition | +25,000 | $20.22 |
| 2026-06-04 | Lesley Calhoun | Independent Director | Other Acquisition | +4,000 | -- |
| 2026-06-04 | Lesley Calhoun | Independent Director | Other Derivative Acquisition | +25,000 | $20.22 |
| 2026-06-04 | John Ketchum | Independent Director | Other Acquisition | +4,000 | -- |
| 2026-06-04 | John Ketchum | Independent Director | Other Derivative Acquisition | +25,000 | $20.22 |
| 2026-06-04 | Sung Lee | Lead Independent Director | Other Acquisition | +570 | -- |
| 2026-06-04 | Sung Lee | Lead Independent Director | Other Derivative Acquisition | +3,570 | $20.22 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:41:45 · For reference only, not investment advice and not tailored to your situation.
Tango Therapeutics discussion 0 comments